ストックスクリーナーアプリを入手
5.625
1.48%
-0.085
前日終値:
$5.71
開ける：
$5.7
24時間の取引高:
759.46K
Relative Volume:
0.17
時価総額：
$1.88B
収益：
$493.67M
当期純損益:
$-104.69M
株価収益率:
-16.54
EPS:
-0.34
ネットキャッシュフロー:
$-31.51M
1週間 パフォーマンス:
-1.82%
1か月 パフォーマンス:
-9.56%
6か月 パフォーマンス:
-42.54%
1年 パフォーマンス:
-43.00%
1日の値動き範囲:
$5.51
$5.71
1週間の範囲:
$5.51
$5.8199
52週間の値動き範囲:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
名前
Amicus Therapeutics Inc
セクター
電話
(609) 662-2000
住所
47 HULFISH STREET, PRINCETON, NJ
FOLD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
5.63 | 1.88B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.72 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.45 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.47 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
562.00 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.63 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 開始されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Wells Fargo | Overweight |
| 2024-05-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 再開されました | Goldman | Neutral |
| 2022-01-14 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | アップグレード | Stifel | Hold → Buy |
| 2021-09-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 再開されました | BTIG Research | Buy |
| 2021-05-27 | 開始されました | Needham | Hold |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2021-02-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-02-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-05 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 開始されました | Janney | Buy |
| 2019-01-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 開始されました | Citigroup | Neutral |
| 2018-08-17 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
| 2017-09-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-08-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-01-24 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 開始されました | BofA/Merrill | Buy |
| 2016-04-14 | 開始されました | Robert W. Baird | Neutral |
| 2016-04-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2015-09-16 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Amicus Therapeutics Inc (FOLD) 最新ニュース
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Turn A Profit? - simplywall.st
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week LowTime to Sell? - MarketBeat
Amicus Therapeutics stock hits 52-week low at 5.79 USD By Investing.com - Investing.com Canada
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.22 Average Price Target from Analysts - MarketBeat
(FOLD) Technical Data - news.stocktradersdaily.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Wedge Capital Management L L P NC - MarketBeat
Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma (NASDAQ:FOLD) - Seeking Alpha
Amicus Therapeutics at Goldman Sachs Conference: Strategic Insights Unveiled By Investing.com - Investing.com Canada
Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - Yahoo Finance
Zacks Research Issues Pessimistic Outlook for FOLD Earnings - MarketBeat
Two Sigma Investments LP Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Therapeutic Market Deep Research Report with - openPR.com
Millennium Management LLC Buys 44,449 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda - GuruFocus
New Strong Sell Stocks for June 3rd - Yahoo Finance
Amicus (FOLD) Reports Positive Findings from PROPEL Study in Pompe Disease | FOLD Stock News - GuruFocus
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve - GlobeNewswire
Clinical Data Reveals Treatment Advantages: 77% of Pompe Disease Patients Show Improvement with New Therapy - Stock Titan
Two Sigma Advisers LP Acquires 52,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Cetera Investment Advisers Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
How to Take Advantage of moves in (FOLD) - news.stocktradersdaily.com
Man Group plc Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 | FOLD Stock News - GuruFocus
Rare Disease Leader Amicus Therapeutics to Present Latest Updates at Major Healthcare Conferences - Stock Titan
Millennium Management LLC Has $4.31 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Voloridge Investment Management LLC Sells 397,497 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Squarepoint Ops LLC Purchases 753,060 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Neo Ivy Capital Management Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Woodline Partners LP Sells 726,952 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Ameriprise Financial Inc. - Defense World
Pompe Disease Market: Epidemiology, Therapies, Companies, - openPR.com
Teza Capital Management LLC Sells 68,066 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Nuveen Asset Management LLC Purchases 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
297,830 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Sovereign s Capital Management LLC - MarketBeat
Vestal Point Capital LP Acquires New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Deutsche Bank AG Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Rafferty Asset Management LLC Sells 73,883 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics Inc (FOLD) 財務データ
収益
当期純利益
現金流量
EPS
Amicus Therapeutics Inc (FOLD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Campbell Bradley L | President and CEO |
Feb 19 '25 |
Sale |
10.00 |
400 |
4,000 |
1,150,657 |
1.81%
大文字化:
|
ボリューム (24 時間):